Published Paper Details:

Fungal infections pose a significant global health threat, particularly among immunocompromised individuals such as cancer patients, organ transplant recipients, and those with HIV/ m, AIDS. Despite advancements, current antifungal therapies face challenges including poor solubility, limited bioavailability, side effects, and rising drug resistance. This review provides a comprehensive overview of the evaluation parameters used in assessing antifungal formulation, focusing on their physicochemical, microbiological, and in vivo characteristics. Key quality control parameters such as appearance, pH, viscosity, spreadability, rheology, and drug content uniformity are discussed alongside advance analytical technique like HPLC, FTIR, DSC, and UV-Vis spectrophotometry. Microbiological assays including zone of inhibition, minimum inhibitory concentration (MIC), and time kill studies are also examined, along with in vitro drug release testing using Franz Diffusion, Dialysis, and Dissolution methods. In vivo evaluations such as skin irritation and therapeutic efficacy tests further ensure safety and performance. Emerging technologies such as nanoparticle, liposomal, and hydrogel based delivery system are explored for improving drug stability, targeting, and patient compliance. The review emphasize the importance of comprehensive evaluation in developing effective, safe, and stable antifungal formulations, highlighting future perspectives involving AI-driven formulation design and eco-friendly materials.